Further Consolidation in Anatomic Pathology
Dianon System's purchase in June of UroCor was hardly surprising, coming after three years of discussions between the two companies. The purchase of UroCor, a disease management company, will fortify Dianon's already strong franchise in urology clinical diagnostics testing. The deal, a stock-for-stock transaction valued at about $180 million, merges two complementary businesses, offering opportunities for synergies and leveraging of operations.
You may also be interested in...
Anatomic pathology is consolidating rapidly due to changes in reimbursement and the looming presence of managed care. The pioneering players, AmeriPath and Dianon, are taking radically different approaches to gaining market share.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.